Table 1 Secondary outcomes
Outcome | Description |
|---|---|
Glaucoma Utility Index (GUI) | A glaucoma-specific treatment-related quality of life specifically designed to capture the impact of glaucoma treatment and disease severity on HRQL. This is the main secondary outcome. |
Glaucoma Symptom Scale (GSS) | A patient-reported disease and treatment related symptoms questionnaire. |
Glaucoma Quality of Life-15 (GQL-15) | A patient-reported visual functioning questionnaire. |
Client Services Receipt Inventory (CSRI) | A validated method of collecting healthcare cost data. This data will be analysed by the health economists. |
Objective measure of pathway effectiveness | Efficacy and intensity of the treatment pathways will be assessed at 3 years. |
Concordance/Compliance | A pair of questions will be asked about drop usage and compliance: 1) ‘Over the past month, what percentage of your drops do you think you took correctly?’ 2) On a Likert scale, participants will be asked to respond to the following statement): ‘I’m the sort of person who follows doctors’ orders exactly’. |
Adverse events | Adverse events possibly associated with treatment will be recorded. Participants will be asked about possible treatment-related side effects using a simple standardised series of closed and open questions at each visit. |